NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up
Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.
How this was made
The 30-second read
Why it matters
Earnings miss on EPS offset by revenue beat and raised guidance; market may react to mixed signals.
Market read
Earnings and guidance update provide fresh material for traders; mixed signals create short‑term volatility.
What to watch
Medicare coverage expansion for organ health testing could drive future growth.
Background
Natera reported Q3 2026 results, highlighting oncology test volume growth, Medicare coverage expansion, and cash generation.
Ticker impact
Q3 2026 earnings released with loss per share miss, revenue beat, and raised 2026 revenue guidance.
likely pressure as market prices in the loss miss, with potential upside from raised revenue guidance
Earnings and guidance are fresh primary disclosures; loss miss is negative, but revenue beat and guidance raise are positive catalysts.
Market effects
Strong revenue growth may lift other genetics testing firms.
Positive for US biotech sector.
Limited to healthcare/diagnostics investors.
Counterpoint
Loss miss suggests valuation compression despite guidance raise.
Key entities
- CompanyNatera
Genomics testing company reporting Q3 results.
